Clearmind Medicine Inc. SEC filings CMND
Clearmind Medicine Inc. has 372 filings in SEC EDGAR's recent list, going back to Dec 23, 2021. Its latest annual report, Form 20-F, was filed on Jan 20, 2026 for the period ended Oct 31, 2025. The most recent current report (Form 6-K) was filed on Oct 27, 2026. The company's fiscal year ends on October 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| POS AM | Post-effective amendment no. 3 to form f-1 | Jun 15, 2026 | — |
| F-3 | Shelf registration (foreign issuer) | Apr 30, 2026 | — |
| POS AM | Post-effective amendment no. 9 to form f-1 | Mar 25, 2026 | — |
| POS AM | Post-effective amendment no. 9 to form f-1 | Mar 25, 2026 | — |
| F-3 | Shelf registration (foreign issuer) | Feb 17, 2026 | — |
| POS AM | Post-effective amendment no. 8 to form f-1 | Jan 27, 2026 | — |
| POS AM | Post-effective amendment no. 8 to form f-1 | Jan 27, 2026 | — |
| POS AM | Post-effective amendment no. 1 to form f-1 | Jan 27, 2026 | — |
| F-1/A | Amendment no. 1 to form f-1 | Dec 5, 2025 | — |
| 424B5 | Prospectus supplement | Dec 3, 2025 | — |
| F-1 | Registration statement (foreign issuer) | Nov 26, 2025 | — |
| 424B5 | Prospectus supplement | Nov 26, 2025 | — |
| 424B5 | Prospectus supplement | Nov 19, 2025 | — |
| 424B5 | Prospectus supplement | Nov 17, 2025 | — |
| 424B5 | Prospectus supplement | Nov 13, 2025 | — |
| F-1 | Registration statement (foreign issuer) | Sep 19, 2025 | — |
| POS AM | Post-effective amendment no.7 to form f-1 | Sep 15, 2025 | — |
| POS AM | Post-effective amendment no. 6 to form f-1 | Jun 12, 2025 | — |
| POS AM | Post-effective amendment no. 5 to form f-1 | Mar 13, 2025 | — |
| POS AM | Post-effective amendment no. 4 to form f-1 | Jan 22, 2025 | — |
| S-8 | Employee stock plan registration | Dec 9, 2024 | — |
| POS AM | Post-effective amendment no. 3 to form f-1 | Sep 24, 2024 | — |
| POS AM | Post-effective amendment no. 2 to form f-1 | Jul 23, 2024 | — |
| 424B3 | Prospectus | Jun 28, 2024 | — |
| POS AM | Post-effective amendment no. 1 to form f-1 | Mar 20, 2024 | — |
| F-1 | Registration statement (foreign issuer) | Feb 7, 2024 | — |
| POS AM | Post-effective amendment no. 1 to form f-1 | Jan 18, 2024 | — |
| 424B5 | Prospectus supplement | Jan 16, 2024 | — |
| F-3/A | Amendment no. 1 to form f-3 | Dec 22, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 11, 2023 | — |
| 424B4 | Prospectus | Sep 18, 2023 | — |
| F-1/A | Amendment no. 2 to form f-1 | Sep 13, 2023 | — |
| F-1/A | Amendment no. 1 to form f-1 | Jul 25, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Jul 17, 2023 | — |
| 424B4 | Prospectus | Apr 5, 2023 | — |
| F-1/A | Amendment no. 2 to form f-1 | Mar 31, 2023 | — |
| F-1/A | Amendment no. 1 to form f-1 | Mar 28, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Mar 27, 2023 | — |
| 424B4 | Prospectus | Nov 16, 2022 | — |
| F-1/A | Amendment no. 9 to form f-1 | Nov 14, 2022 | — |
| F-1/A | Amendment no. 8 to form f-1 | Nov 9, 2022 | — |
| F-1/A | Amendment no.7 to form f-1 | Nov 4, 2022 | — |
| F-1/A | Amendment no. 6 to form f-1 | Nov 2, 2022 | — |
| F-1/A | Amendment no. 5 to form f-1 | Oct 26, 2022 | — |
| FWP | Free writing prospectus | Oct 24, 2022 | — |
| F-1/A | Amendment no. 4 to form f-1 | Oct 20, 2022 | — |
| F-1/A | Amendment no. 3 to form f-1 | Oct 6, 2022 | — |
| F-1/A | Amendment no. 2 to form f-1 | Sep 21, 2022 | — |
| F-1/A | Amendment no. 1 to form f-1 | Aug 18, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Jun 29, 2022 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CMND (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Vancouver, British Columbia, Canada (Federal Level)
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1892500
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.